Assessment of Beta Cell Mass by PET Scans With [11C] Dihydrotetrabenazine (DTBZ) in Longstanding Type 1 Diabetes.
Type 1 Diabetes
|Study Design:||Observational Model: Case Control
Time Perspective: Cross-Sectional
|Official Title:||Assessment of Beta Cell Mass by PET Scans With [11C] DTBZ in Longstanding Type 1 Diabetes|
- Pancreatic tracer binding as standardized uptake value (SUV) or binding potential (BPnd) [ Time Frame: measured over 60-120 minutes ] [ Designated as safety issue: No ]Reflects tissue density of biomarker
|Study Start Date:||November 2006|
|Study Completion Date:||May 2008|
|Primary Completion Date:||January 2008 (Final data collection date for primary outcome measure)|
Diabetes results when the insulin secretory capacity of the beta cell population is lost or severely compromised. Plasma insulin levels have been used as a surrogate marker of beta cell mass (BCM) but insulin levels often do not correlate well with BCM and a "gold standard of measurement" to obtain this type of information would be of great value. The aim of the proposed study is to evaluate an islet imaging technique using PET scanning that will be able to be used for directly measuring BCM and thus provide valuable information for monitoring disease progress and response to therapy in people with diabetes and in people at high risk for diabetes. Type 1 diabetes (T1DM) occurs when the beta cells are selectively destroyed by a T cell mediated autoimmune process. People at high risk for developing T1DM, such as first degree relatives of patients with T1DM, can be sometimes be identified before the disease develops by measuring autoantibodies to beta cells, however this test is neither very sensitive or specific. In contrast, type 2 diabetes (T2DM) occurs in a setting of insulin resistance leading to hyperinsulinemia. In people at high risk for T2DM, beta cell mass increases to meet the demand for more insulin. The individual becomes diabetic when the BCM and insulin production can no longer compensate for the increased need for insulin, and blood glucose begins to rise. Loss of BCM may then occur as T2DM advances. People at high risk for T2DM include first degree relatives of patients with T2DM and those with obesity, insulin resistance and the metabolic syndrome. Little is known about the natural history of BCM, turnover and cell lifetime, or the course of inflammation in diabetes. This is principally because the pancreas is a highly heterogeneous organ that is difficult to biopsy without significant complications, and BCM is only 1-2% of the organ. Accurate assessment of BCM in human diabetes is limited to autopsy studies, which usually suffer from inadequate clinical information; thus, the development of noninvasive means of BCM measurement could be important, not only in intervention therapy of T1DM and T2DM, islet regeneration/stem cell therapy and islet transplantation.
Until recently, islet cell mass visualization has not been clinically feasible. We have previously identified a specific marker on pancreatic beta cells called vesicular monoamine transporter type 2 (VMAT2). In preclinical studies, we have shown that imaging beta cell mass with PET scanning using this radioligand is feasible in rats and in dosimetry studies conducted in baboons. This radioligand, [11C]DTBZ, has been used previously in human subjects in clinical trials evaluating P.E.T scanning of the brain in patients with bipolar illness and schizophrenia compared to healthy control subjects. In the current protocol, we propose to use a radioligand, [11C]DTBZ, that binds to VMAT2 in positron emission tomography (PET) scanning to assess whether PET can measure beta cell mass in human subjects.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00738907
|Principal Investigator:||PAUL HARRIS, PH.D||Columbia University|